Compare GCBC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GCBC | CBIO |
|---|---|---|
| Founded | 1889 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 389.7M |
| IPO Year | 1998 | N/A |
| Metric | GCBC | CBIO |
|---|---|---|
| Price | $22.30 | $11.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 8.6K | ★ 181.9K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 26.21 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.66 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $20.00 | $8.72 |
| 52 Week High | $26.21 | $17.39 |
| Indicator | GCBC | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 57.59 |
| Support Level | $21.39 | $11.88 |
| Resistance Level | $23.48 | $13.37 |
| Average True Range (ATR) | 0.83 | 1.01 |
| MACD | -0.10 | 0.12 |
| Stochastic Oscillator | 19.70 | 68.65 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.